ABSTRACT
INTRODUCTION
Natural products are the most consistent successful source of drug leads (1−3) . Plants supply most of the active ingredients of traditional medicinal products (4−6) . The fight against cancer will continue to require the development of novel and improved chemotherapeutic agents. Drug discovery from plants involves a multidisciplinary approach combining botanical, ethnobotanical, phytochemical and biological technologies. Plants in particular have a long history of use in the treatment of cancer (7) .
The genus Tillandsia is a group of epiphytic plants with approximately 500 species (8) . There are no reports of traditional use of Ball Moss in Jamaica; however, the plant is used in folk medicine in Brazil, Bolivia, Mexico and the United States of America [USA] (9−13). Research has shown its potential medicinal value in treating hypoglycaemia, rheumatoid arthritis and liver infections (14) and the ground breaking anti-cancer effect of this plant was discovered in 2007 (15) . In addition, research has identified several phytochemicals from the plant and these include: cycloartane triterpenoids, pentacyclic triterpenes, sterols and flavonoids (16, 17) . This paper describes the anti-cancer properties of the Jamaican ball moss.
METHODS

Plant collection and preparation
T recurvata (Fig. 1 ) was collected from trees and electrical poles in Kingston, Jamaica. A voucher specimen of the plant was identified at the Institute of Jamaica Herbarium where it was deposited with accession number: IJ 3411. The collected biomass was air dried under shade and pulverized into powder.
Extraction and isolation 1 kg of ball moss biomass was extracted twice with 5L of methanol. The filtrate was dried in a rotavapor to obtain a dark green residue (16.3 g). The extract was stored in a refrigerator at 4°C until needed for use in the bioassay.
Biological assay
Cell lines and culture medium Five different histogenic tumours (prostate cancer, PC-3; breast cancer, BC; Kaposi sarcoma, KS; B-16 melanoma and a B-cell lymphoma) from a transgenic mouse strain were used in the study. The cell lines were obtained from American Type Culture Collection (ATCC) [Manassas, VA, USA] or from in-house cultures, specifically KS and the Bcell lymphoma from an HIV-1 transgenic mouse. The cells were maintained in minimum essential media supplemented with 10% fetal calf serum, 1% L-glutamine, 2% penicillinstreptomycin, and 0.2% gentamicin at 37°C with 5% CO 2 . Cell death/viability was measured by the trypan blue exclusion assay protocol (18) .
Extract preparation and treatment
The dried crude extract of ball moss formulated was in dimethyl sulfoxide (DMSO) and normal saline (2:8). The drug concentration was 1 mg/ml and each mouse was administered 0.2 ml, giving a dose of 10 mg/kg. The vehicle was prepared using the same diluent concentrations without the extract.
In vivo maximum tolerable dose study
Mice used were purchased from Harlan Sprague Dawley (Indianapolis, Indiana) and maintained in a pathogen-free environment in the Institute of Human Virology Animal Facility in the University of Maryland School of Medicine. All experiments involving mice were approved by the Institutional Animal Care and Use Committee at the University of Maryland School of Medicine. To determine the maximum tolerable dose (MTD) for the experiment, 15 nude mice were divided into three equal groups. Two of the groups were respectively treated with 100 mg/kg and 200 mg/kg IP using a crude ball moss extract daily for five days and the third group was treated with the vehicle control. The MTD was found to be > 200 mg/kg and it was thus determined that it was safe to use any of the two concentrations or lower in the efficacy study.
In vivo efficacy study From the above MTD studies, we used the 10 mg/kg for treatment of the tumours in the mice. All mice were maintained as described above. Thirty nu/nu (NIH) mice, four to six weeks old were inoculated with 3 x 10 6 Kaposi sarcoma cancer cells in 33% matrigel/67% media with no fetal calf serum (FCS). When tumours reached~100 mm 3 , the mice were divided into two groups of eight mice each so that the Lowe et al mean tumour volume was similar. Dosing was initiated on the day of sorting. Mice were dosed daily for a total of 30 days orally. The body weight of mice was taken alongside tumour volumes twice a week and the tumour volumes determined using the following formula: L x W 2 /2 (L = tumour length; W = tumour width)
Assessment of apoptosis
The Apoptag kit (Intergen, Purchase, NY) was used to determine effect on apoptosis according to the manufacturer's instructions. After light counterstaining with haematoxylin (H&E), nuclei that stained brown were scored as positive for apoptosis and those that stained blue were scored as negative.
RESULTS
In vitro anti-proliferation activity
The results of the in vitro anti-proliferation assay results are presented in Fig. 2 . All the five cancer cell lines showed sensitivity to the ball moss extract with the breast cancer cell line showing the most sensitivity and the Kaposi sarcoma cell line showing lower sensitivity.
Apoptosis assay
The five tumours that were passed in vivo were tested and on histological examination, all tumours showed necrosis on H&E. Histologically, using the immunohistochemical staining (Apoptag), all tumours showed clear evidence of brown staining, demonstrating apoptosis. A representative sample of the histology and the Apoptag staining are demonstrated in Fig. 3 . 
In vivo anti-tumour activity
Treating of mice injected with Kaposi sarcoma cells resulted in significant arrest of tumour growth compared to control (p < 0.05). Figure 4 presents the results of the in vivo efficacy studies. The concentration used was selected based on the MTD study results where ball moss was found to be safe at up to 200 mg/kg by oral gavage. Haematoxylin staining of tumour cells harvested from treated and control mice showed significant difference in cell morphology.
DISCUSSION
On the basis of the observed in vitro and in vivo activities of ball moss, our hypothesis that this plant possesses unique compounds based on the environment that it grows in has been confirmed in these preliminary set of studies. The plant extract has demonstrated activity against five major cancer cell lines in vitro as well as in vivo activity against Kaposi sarcoma which is one of the HIV-related cancers currently plaguing the AIDS community. Efforts to determine the mechanism of action has indicated that ball moss exhibit its activity against cancer cells by triggering the process of apoptosis (Fig. 3) . Apoptosis or programmed cell death involves the activation of a set of cysteine proteases known as "caspases" (19) .
The study presented here demonstrated the anti-cancer properties of T recurvata extract against tumours of different histogenic origins. This observation of a crude extract showing strong anti-cancer properties supports the importance of studying this plant with unique bioactive metabolites. We are currently in the process of determining the specific compound(s) responsible for the anti-cancer activity demonstrated by the plant extract in this study.
